Investor Presentation - First Six Months of 2021

14 Investor presentation First six months of 2021 R&D milestones Diabetes care Project OzempicⓇ FDC Sema - OW GIP Cagrisema Glucose sensitive insulin Obesity care Q2 2021 ✓ SUSTAIN FORTE US resubmission Q3 2021 Q4 2021 SUSTAIN FORTE Phase 2 initiation ✓ Phase 2 initiation Phase 1 results EU decision Ideal Pump Insulin Phase 1 results Semaglutide 2.4 mg ✓ US decision Oral sema 50 mg LA-GDF15 EU decision Phase 3 initiation Novo NordiskⓇ Clinical milestones¹ Regulatory milestones¹ Q1 2022 SUSTAIN FORTE US decision Phase 1 results Phase 3 results in GHD2 Biopharm Sogroya® (somapacitan) Mim8 Sema NASH Phase 3 initiation (F2-F3) Phase 1/2 results Phase 2 results (F4) Other serious chronic diseases NASH - combination with Gilead Phase 2b initiation Ziltivekimab Oral PCSK9i Phase 3 initiation ✓ Phase 2 initiation Sema in Alzheimer's disease ✓ Phase 3 initiation 1 Expected to be published in the given quarter or in the subsequent quarterly company announcement, 2 GHD includes growth hormone in children, trial read-out expected around the turn of the year Note: Trial initiations could be impacted by COVID-19, NASH: Non-alcoholic steatohepatitis; (A)GHD: (Adult) Growth Hormone Deficiency; Sema: Semagtide; HFPEF: Heart Failure with preserved Ejection Fraction The timelines for cagrisema (cagrilintide, previously denoted AM833, + semaglutide 2.4 mg) in Obesity have moved

View entire presentation